Mint Tower Capital Management B.V. Takes $1.53 Million Position in Kenvue Inc. $KVUE

Key Points

• Mint Tower Capital Management purchased 80,000 Kenvue shares in the second quarter, valued at approximately $1.53 million. Institutional investors collectively own 97.64% of the company.
• Kenvue’s latest quarterly results slightly missed expectations, with earnings of $0.31 per share and revenue of $3.96 billion, though revenue increased 3% year over year.
• The stock traded near $19.15, while analysts maintained a generally cautious outlook: three rated it Buy and twelve rated it Hold. Kenvue pays a quarterly dividend of $0.21, representing a 4.4% annualized yield.

Mint Tower Capital Management B.V. bought a new position in Kenvue Inc. (NYSE:KVUE - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The fund bought 80,000 shares of the company's stock, valued at approximately $1,529,000.

Several other large investors have also recently modified their holdings of the stock. Elyxium Wealth LLC purchased a new stake in shares of Kenvue in the fourth quarter valued at $26,000. Johnson Financial Group Inc. bought a new stake in shares of Kenvue in the 2nd quarter worth about $26,000. MV Capital Management Inc. purchased a new position in shares of Kenvue during the 4th quarter worth about $28,000. CoreCap Advisors LLC grew its holdings in Kenvue by 64.9% during the 2nd quarter. CoreCap Advisors LLC now owns 1,502 shares of the company's stock valued at $29,000 after purchasing an additional 591 shares during the last quarter. Finally, Reflection Asset Management bought a new position in Kenvue during the 4th quarter valued at about $32,000. Institutional investors own 97.64% of the company's stock.

Kenvue Stock Down 0.3%

Shares of NYSE:KVUE opened at $19.15 on Friday. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $20.82. The stock has a market cap of $36.78 billion, a P/E ratio of 22.01, a price-to-earnings-growth ratio of 1.37 and a beta of 0.47. The business's 50 day moving average is $19.16 and its 200 day moving average is $18.25. The company has a quick ratio of 0.71, a current ratio of 1.01 and a debt-to-equity ratio of 0.67.

Kenvue (NYSE:KVUE - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $0.31 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by ($0.01). Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The firm had revenue of $3.96 billion for the quarter, compared to the consensus estimate of $3.97 billion. During the same period last year, the firm earned $0.29 earnings per share. The company's revenue for the quarter was up 3.0% on a year-over-year basis. Sell-side analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th were issued a $0.21 dividend. The ex-dividend date was Wednesday, August 12th. This is an increase from Kenvue's previous quarterly dividend of $0.21. This represents a $0.84 annualized dividend and a dividend yield of 4.4%. Kenvue's dividend payout ratio is presently 96.55%.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on KVUE. UBS Group decreased their price objective on shares of Kenvue from $20.00 to $19.00 and set a "neutral" rating for the company in a research note on Tuesday, August 11th. Zacks Research downgraded Kenvue from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 7th. Wall Street Zen lowered Kenvue from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Weiss Ratings upgraded Kenvue from a "hold (c-)" rating to a "hold (c)" rating in a report on Monday, June 15th. Finally, Barclays upped their price objective on Kenvue from $18.00 to $19.00 and gave the company an "equal weight" rating in a research report on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company's stock. According to MarketBeat.com, Kenvue currently has an average rating of "Hold" and an average price target of $19.27.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source